J
Jamie J. Manning
Researcher at University of Otago
Publications - 11
Citations - 155
Jamie J. Manning is an academic researcher from University of Otago. The author has contributed to research in topics: Cannabinoid receptor & Cannabinoid. The author has an hindex of 5, co-authored 8 publications receiving 71 citations. Previous affiliations of Jamie J. Manning include University of Auckland.
Papers
More filters
Journal ArticleDOI
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
David B. Finlay,David B. Finlay,Jamie J. Manning,Jamie J. Manning,Mikkel Søes Ibsen,Christa MacDonald,Monica Patel,Monica Patel,Jonathan A. Javitch,Samuel D. Banister,Michelle Glass,Michelle Glass +11 more
TL;DR: A basic molecular pharmacology characterization of AMB-FUBINACA in comparison to traditional research cannabinoids CP55,940, WIN55,212-2, and Δ9-THC in fundamental pathways of receptor activity revealed that it is highly efficacious and potent in all pathways assayed.
Journal ArticleDOI
Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
Monica Patel,Jamie J. Manning,David B. Finlay,Jonathan A. Javitch,Samuel D. Banister,Natasha L. Grimsey,Michelle Glass +6 more
TL;DR: While the majority of SCRAs demonstrated robust β-arrestin translocation, cAMP stimulation, and internalisation, THC failed to elicit high efficacy responses in any of these assays, and further study is required to delineate if these pathways could contribute to SCRA toxicity in humans.
Journal ArticleDOI
CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist
Richard C. Kevin,Lyndsey L. Anderson,Iain S. McGregor,Rochelle Boyd,Jamie J. Manning,Michelle Glass,Mark Connor,Samuel D. Banister +7 more
TL;DR: It is reported here that CUMYL-4CN-BINACA is a potent CB1 receptor agonist that produces pro-convulsant effects in mice at a lower dose than reported for any SCRA to date, and may underpin the toxicity associated with this compound in humans.
Journal ArticleDOI
Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
TL;DR: The type-1 cannabinoid receptor (CB1) is a promising drug target for a wide range of diseases as discussed by the authors, however, many existing and novel candidate ligands for CB1 have shown only limited therapeutic potential.
Journal ArticleDOI
The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F‐PY‐PICA, 5F‐PY‐PINACA, and their analogs
Samuel D. Banister,Samuel D. Banister,Richard C. Kevin,Lewis J. Martin,Axel Adams,Christa MacDonald,Jamie J. Manning,Rochelle Boyd,Michael. J. Cunningham,Marc Y. Stevens,Iain S. McGregor,Michelle Glass,Mark Connor,Roy Gerona +13 more
TL;DR: Five SCRA NPS evaluated in vivo using radio biotelemetry did not produce cannabimimetic effects in mice at doses up to 10 mg/kg and expansion of the pyrrolidine ring of 5F-PY-PICA to an azepane conferred the greatest hCB2 affinity and activity within the series.